DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.
Le TK, Cherif C, Omabe K, Paris C, Lannes F, Audebert S, Baudelet E, Hamimed M, Barbolosi D, Finetti P, Bastide C, Fazli L, Gleave M, Bertucci F, Taïeb D, Rocchi P.
Le TK, et al. Among authors: omabe k.
Mol Ther. 2023 Feb 1;31(2):471-486. doi: 10.1016/j.ymthe.2022.08.005. Epub 2022 Aug 13.
Mol Ther. 2023.
PMID: 35965411
Free PMC article.